Compare NXDT & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXDT | NERV |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.1M | 301.6M |
| IPO Year | N/A | 2014 |
| Metric | NXDT | NERV |
|---|---|---|
| Price | $4.99 | $4.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | ★ 145.9K | 120.8K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $1.57 |
| 52 Week High | $5.61 | $12.46 |
| Indicator | NXDT | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 36.18 |
| Support Level | $4.48 | $4.30 |
| Resistance Level | $5.55 | $4.59 |
| Average True Range (ATR) | 0.26 | 0.37 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 19.87 | 13.70 |
NexPoint Diversified Real Estate Trust is an externally advised REIT focused on the acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties throughout the United States. The company has two reportable segments: The Diversified reportable segment is focused on investing in various commercial real estate property types and across the capital structure, including but not limited to, equity, mortgage, debt, mezzanine debt and preferred equity. The Hospitality segment is focused on operating and renovating its U.S. located hospitality assets that meet its investment objective and criteria. Its Portfolio includes investments in the single-family rental, self-storage, office, hospitality, life science and multifamily sectors.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.